CHICAGO – Patients who have a heart defect known as patent foramen ovale incidentally discovered and repaired during surgery for a different condition may have an increased odds of postoperative ...

Patients with simple coronary heart disease (CHD) who underwent CHD surgery had a lower risk for epilepsy than those who did not undergo surgery. HealthDay News — Among simple congenital heart ...

TCT 602: Feasibility and Safety of Same Day Discharge for Patent Forman Ovale Closures Using Intracardiac Echo and Moderate Sedation Receive the the latest news, research, and presentations from major ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

A patent foramen ovale or PFO is a defect in the wall between the two upper chambers of the heart. This defect is actually an incomplete closure of the atrial wall that results in a flap or valve-like ...

Editor's Note: This article is made possible through a sponsored content partnership with New Hanover Regional Medical Center. Structural heart disease includes conditions in which the heart’s valves, ...

The echocardiogram shows the incidental finding of an aneurysm of the interatrial septum (IAS). Aneurysms of the IAS are fairly common and occur with an incidence of 2% to 8%. The size and morphology ...

An atrial septal defect is a congenital heart issue. According to the Centers for Disease Control and Prevention (CDC), it develops in about 1 in 1,859 babies in the United States. An atrial septal ...

Over the past years, many researchers have been engaged in deciphering the interrelationship between migraine and patent foramen ovale (PFO) and have tried to answer the question of whether PFO ...

LONDON--(BUSINESS WIRE)--The global heart defect closure devices market research report by Technavio predicts the market to post a CAGR of more than 29% during the period 2019-2023. A key driver for ...

Encore Medical, Inc. seeks $17.25 million in IPO funding to support US FDA trials for its heart defect closure device. EMI has CE Mark approval in the EU but limited recent sales; US clinical trial ...